InnoCan - Founder and CEO, Iris Bincovich.
Founder and CEO, Iris Bincovich.
Source: The Investor Coliseum.
  • InnoCan Pharma’s (INNO) Israeli subsidiary has entered a manufacturing and distribution agreement with cannabis extractor, Endless Sky Inc
  • Under the agreement, Endless Sky will manufacture and distribute InnoCan’s CBD cosmetic products in Canada
  • The agreement covers products including Relief & GO CBD Spray and Cream, SHIR Eye Serum, Face Cream, and Night Cream
  • Endless Sky will pay InnoCan Israel a cash license fee per product, plus royalties based on product sales
  • InnoCan Pharma (INNO) is up 4.55 per cent and is currently trading at C$0.23 per share

InnoCan Pharma’s (INNO) Israeli subsidiary has entered a manufacturing and distribution agreement with cannabis extractor, Endless Sky Inc.

Endless Sky is a large-scale cannabis CO2 extractor, based in Calgary, Alberta. The company’s standard processing licence from Health Canada allows it to produce consumer packaged goods with cannabinoid additives.

Under the agreement, Endless Sky will manufacture and distribute InnoCan’s CBD cosmetic products in Canada. The products will be made at Endless Sky’s Health Canada-licensed facility in Redvers, Saskatchewan. 

Under a license granted by InnoCan, Endless Sky will act as the exclusive distributor for specific products. 

The agreement gives Endless Sky manufacturing and distribution rights to a range of CBD-infused cosmetic products. These include the Relief & Go CBD Spray and Cream, the SHIR Eye Serum, Face Cream, and Night Cream.

Endless Sky will pay InnoCan Israel a cash license fee per product, plus royalties based on product net sales.

InnoCan Israel and Endless Sky’s agreements depends on the latter receiving Health Canada’s approval by December 31, 2020. The agreement will have a one-year term but will be automatically extended for another year each time Endless Sky achieves minimum sales targets.

InnoCan’s founder and CEO, Iris Bincovich, commented on the company’s agreement with Endless Sky.

“We are thrilled to have found the right party to distribute and manufacture our CBD line of products in Canada.

“Distributing our CBD line of products is a significant milestone for us, given the importance of Canada to the world of CBD.

“Collaboration with Endless Sky, one of Canada’s largest extracting companies, will allow us to enter InnoCan’s revolutionary wellness brands into the Canadian market,” she said.

InnoCan Pharma (INNO) is up 4.55 per cent and is trading at C$0.23 per share at 11:44am EDT.

More From The Market Herald

The Market Herald’s Weekly Cannabis Report – Dec. 8, 2023

Investors in the cannabis industry have had their eyes on Canopy Growth stock, considering its potential for growth and profitability.

Buzz on the Bullboards: Who’s taking off and who’s grounded

As everyone races toward the finish line, let’s take a look at some of the stocks that are standing out from the rest.

Cannara reports record growth and profitability in Q4 2023

Cannabis producer Cannara Biotech Inc. (TSXV:LOVE) reported record growth and profitability in its Q4 and 2023 fiscal year results.

Will Canopy Growth stock recover?

Cannabis Investors have had their eyes on Canopy Growth (TSX:WEED) stock, considering its potential for growth and profitability.